Ghent University Academic Bibliography

Advanced

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps

Gevaert, Philippe UGent, Lang-Loidolt, Doris, Lackner, Andreas, Stammberger, Heinz, Staudinger, Heribert, Van Zele, Thibaut UGent, Holtappels, Gabriële UGent, Tavernier, Jan UGent, Van Cauwenberge, Paul and Bachert, Claus UGent (2006) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 118(5). p.1133-1141
abstract
Background: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. Objectives: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. Methods: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. Results: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels (> 40 pg/mL) predict the response to anti-IL-5 treatment. Conclusion: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. Clinical implications: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
HYPERREACTIVITY, anti-IL-5, INDUCED AIRWAY HYPERRESPONSIVENESS, HUMAN INTERLEUKIN-5 RECEPTOR, ANTI-INTERLEUKIN-5 ANTIBODY, DECREASED EXPRESSION, HUMAN EOSINOPHILS, ALPHA EXPRESSION, ASTHMA, MEMBRANE, CYTOKINES, IL-5 receptor alpha, IL-5, eosinphils, nasal polyps, chronic rhinosinusitis
journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
J. Allergy Clin. Immunol.
volume
118
issue
5
pages
1133 - 1141
Web of Science type
Article
Web of Science id
000244282300020
JCR category
ALLERGY
JCR impact factor
8.829 (2006)
JCR rank
1/16 (2006)
JCR quartile
1 (2006)
ISSN
0091-6749
DOI
10.1016/j.jaci.2006.05.031
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
360715
handle
http://hdl.handle.net/1854/LU-360715
date created
2007-03-30 11:10:00
date last changed
2016-12-19 15:44:09
@article{360715,
  abstract     = {Background: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. 
Objectives: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. 
Methods: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. 
Results: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels ({\textrangle} 40 pg/mL) predict the response to anti-IL-5 treatment. 
Conclusion: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. 
Clinical implications: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.},
  author       = {Gevaert, Philippe and Lang-Loidolt, Doris and Lackner, Andreas and Stammberger, Heinz and Staudinger, Heribert and Van Zele, Thibaut and Holtappels, Gabri{\"e}le and Tavernier, Jan and Van Cauwenberge, Paul and Bachert, Claus},
  issn         = {0091-6749},
  journal      = {JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY},
  keyword      = {HYPERREACTIVITY,anti-IL-5,INDUCED AIRWAY HYPERRESPONSIVENESS,HUMAN INTERLEUKIN-5 RECEPTOR,ANTI-INTERLEUKIN-5 ANTIBODY,DECREASED EXPRESSION,HUMAN EOSINOPHILS,ALPHA EXPRESSION,ASTHMA,MEMBRANE,CYTOKINES,IL-5 receptor alpha,IL-5,eosinphils,nasal polyps,chronic rhinosinusitis},
  language     = {eng},
  number       = {5},
  pages        = {1133--1141},
  title        = {Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps},
  url          = {http://dx.doi.org/10.1016/j.jaci.2006.05.031},
  volume       = {118},
  year         = {2006},
}

Chicago
Gevaert, Philippe, Doris Lang-Loidolt, Andreas Lackner, Heinz Stammberger, Heribert Staudinger, Thibaut Van Zele, Gabriële Holtappels, Jan Tavernier, Paul Van Cauwenberge, and Claus Bachert. 2006. “Nasal IL-5 Levels Determine the Response to anti-IL-5 Treatment in Patients with Nasal Polyps.” Journal of Allergy and Clinical Immunology 118 (5): 1133–1141.
APA
Gevaert, Philippe, Lang-Loidolt, D., Lackner, A., Stammberger, H., Staudinger, H., Van Zele, T., Holtappels, G., et al. (2006). Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 118(5), 1133–1141.
Vancouver
1.
Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2006;118(5):1133–41.
MLA
Gevaert, Philippe, Doris Lang-Loidolt, Andreas Lackner, et al. “Nasal IL-5 Levels Determine the Response to anti-IL-5 Treatment in Patients with Nasal Polyps.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 118.5 (2006): 1133–1141. Print.